HLA-Matched Sibling Transplantation for Severe Aplastic Anemia: Impact of HLA DR15 Antigen Status on Engraftment, Graft-versus-Host Disease, and Overall Survival

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 9, 2012, Pages 1401-1406

  Battiwalla, Minoo ^a   Wang, Tao ^b   Carreras, Jeanette ^b   Deeg, H Joachim ^c   Ayas, Mouhab ^d   Bajwa, Rajinder P S ^e   George, Biju ^f   Gupta, Vikas ^g   Pasquini, Ricardo ^h   Schrezenmeier, Hubert ⁱ   Passweg, Jakob R ^j   Schultz, Kirk R ^k   Eapen, Mary ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c USA   (United States)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f CHRISTIAN MEDICAL COLLEGE   (India)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ FREIE UNIVERSITÄT BERLIN   (Germany)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k BC CHILDREN S HOSPITAL   (Canada)

more..

Author keywords

DR15; Graft failure; GVHD; SAA; Survival

Indexed keywords

HLA DR15 ANTIGEN;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; ENGRAFTMENT; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; SEVERE APLASTIC ANEMIA; SIBLING;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA-DR SEROLOGICAL SUBTYPES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84865157149     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.02.007     Document Type: Article

References (30)

1. Middleton D., Menchaca L., Rood H., Komerofsky R. New allele frequency database. Tissue Antigens 2003, 61:403-407. http://www.allelefrequencies.net.
2. Chapuis B., Von Fliedner V.E., Jeannet M., et al. Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol 1986, 63:51-57.
3. Nakao S., Yamaguchi M., Saito M., et al. HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol 1992, 40:239-240.
4. Nimer S.D., Ireland P., Meshkinpour A., Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994, 84:923-927.
5. Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
6. Shao W., Tian D., Liu C., Sun X., Zhang X. Aplastic anemia is associated with HLA-DRB1*1501 in northern Han Chinese. Int J Hematol 2000, 71:350-352.
7. Song E.Y., Park S., Lee D.S., Cho H.I., Park M.H. Association of human leukocyte antigen-DRB1 alleles with disease susceptibility and severity of aplastic anemia in Korean patients. Hum Immunol 2008, 69:354-359.
8. Sugimori C., Yamazaki H., Feng X., et al. Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia. Exp Hematol 2007, 35:13-20.
9. Feng X., Chuhjo T., Sugimori C., et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2004, 104:2425-2431.
10. Oguz F.S., Yalman N., Diler A.S., Oguz R., Anak S., Dorak M.T. HLA-DRB1*15 and pediatric aplastic anemia. Haematologica 2002, 87:772-774.
11. Usman M., Adil S.N., Moatter T., Bilwani F., Arian S., Khurshid M. Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy. J Pak Med Assoc 2004, 54:251-254.
12. Ilhan O., Beksac M., Koc H., et al. HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood 1995, 86:2055.
13. Battiwalla M., Hahn T., McCarthy P.L. HLA DR15 and immunobiologic outcomes. Biol Blood Marrow Transplant 2007, 13:371.
14. Battiwalla M., Hahn T., Radovic M., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 2006, 107:1970-1973.
15. Davidson J.A., Tate D.G., Poulton K.V., et al. HLA-DR15, reduced relapse rate and improved survival after HLA identical sibling hemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:493-494.
16. Stern M., Passweg J., Tiercy J.M., et al. Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1169-1175.
17. Newell L.F., Gooley T., Hansen J.A., Stirewalt D.L., Petersdorf E.W., Deeg H.J. Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Biol Blood Marrow Transplant 2010, 16:1700-1706.
18. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974, 18:295-304.
19. Kalbfleish J., Prentice R. The Statistical Analysis of Failure Time Data 1980, Wiley, New York.
20. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958, 53:457-481.
21. Cox D.R. Regression models and life-tables. J R Stat Soc Series B (Methodol) 1972, 34:187-220.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
23. Flowers M.E., Kansu E., Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999, 13:1091-1112. viii-ix.
24. Klein J.P., Anderson P.K. Regression modeling of competing risks data based on pseudo-values of the cumulative incidence function. Biometrics 2005, 61:223-229.
25. Klein J.P. Modeling competing risks in cancer studies. Stat Med 2006, 25:1015-1034.
26. Schrezenmeier H., Passweg J.R., Marsh J.C., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007, 110:1397-1400.
27. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007, 109:4582-4585.
28. Passweg J.R., Socie G., Hinterberger W., et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood 1997, 90:858-864.
29. Champlin R.E., Horowitz M.M., van Bekkum D.W., et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989, 73:606-613.
30. Horan J.T., Carreras J., Tarima S., et al. Risk factors affecting outcome of second HLA-matched sibling donor transplantations for graft failure in severe acquired aplastic anemia. Biol Blood Marrow Transplant 2009, 15:626-631.